27 results about "Donor derived" patented technology

Described herein are kits, compositions, and methods for detecting porcine antigens in biological samples. The kit comprises a support, anti-porcine antibodies coupled to the support, and instructions for preparing lysates from a porcine donor source and contacting the lysates with the anti-porcine antibodies. The kit may be for use in determining the risk of transplant rejection in a human subject receiving or being considered for receiving a transplant from the porcine donor.

This invention discloses an artificial corneal endothelial graft based on natural degradable proteins, its preparation method, and its application, relating to the field of medical implant materials technology. Currently, artificial corneal endothelial grafts for corneal endothelial decompensation are all non-degradable synthetic polymer materials. This invention uses a natural degradable material as the substrate to prepare the graft. A material preparation stock solution is obtained by mixing a silk fibroin solution extracted from a high-salt solution with a certain proportion of glycerol. The mixed solution is then spin-coated onto a mold using a gradient method, and dried to obtain a silk fibroin film. The obtained silk fibroin film is then circumcised and placed in a mold for hot-press steam fumigation. The resulting silk fibroin film can serve as an artificial corneal endothelial graft, providing a donor source for artificial corneas and possessing potential application value in corneal transplantation.

The present invention relates to a method for selecting a donor source for NK cells with enhanced proliferative capacity, wherein specific single nucleotide polymorphisms (SNPs) of the CISH gene are identified. According to the present invention, in the context of cell therapy including NK cells, the method solves the problem that the efficacy of NK cells differs according to the difference of donor sources, thereby enabling the production of NK cells having excellent proliferation ability and stable quality.

The invention discloses a novel ALS disease model and application thereof in screening ALS treatment drugs, and belongs to the technical field of disease models and drug screening. According to the method, induced pluripotent stem cells derived from a sporadic ALS patient are directionally induced into spinal cord organs, the spinal cord organs and immune cells derived from the same donor form a co-culture system, the co-culture system is infected with viruses, and the ALS disease model is successfully constructed. According to the method, ALS diseases are simulated on the three-dimensional level, ALS disease models of all stages (including the initial stage of the diseases) are obtained, and the pathological features of all the disease stages of ALS (especially 90% or above of sporadic ALS) can be accurately reflected; the problem that key disease-promoting factors in the early stage of the disease cannot be obtained due to complete disorder of downstream signal channels in the end stage of the disease after definite diagnosis caused by slow definite diagnosis of hidden disease onset of the ALS is solved.

The present invention relates to a method of selecting a donor source for NK cells with enhanced proliferative capacity, wherein specific single nucleotide polymorphisms (SNPs) of the CISH gene are identified. According to the present invention, in the context of cell therapy comprising NK cells, the method addresses the issue of varying efficacy of NK cells depending on the donor source, thereby enabling the production of NK cells with superior proliferative capacity and consistent quality.

The invention relates to a method for evaluating the biological value of mesenchymal stem cells, and belongs to the technical field of biology. The method comprises the following steps: firstly, respectively collecting conditioned culture media of mesenchymal stem cells from different donor sources and mesenchymal stem cells expressed by silence TSP2, and detecting the concentration of TSP2 in the culture media by adopting an enzyme-linked immunosorbent assay method; furthermore, inflammatory factors are used for inducing cartilage cells, a conditioned culture medium is replaced for culture for 24 h, then the cells are collected, messenger RNA (mRNA) expression change of II-type collagen of the cells is detected, and the correlation between the TSP2 concentration of the conditioned culture medium and the mRNA expression abundance of the II-type collagen of the cartilage cells is established; the TSP2 concentration in the mesenchymal stem cell culture supernatant is measured, the TSP2 concentration can be used for evaluating the biological value of the mesenchymal stem cells in cartilage regeneration and protection in treatment of osteoarthritis and other degenerative diseases, and a reliable basis is provided for standardization and quality control of mesenchymal stem cell treatment.

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and / or senescent cells. The donor quiescent and / or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and / or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ε-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.

Human embryonic stem cell (hESC)- and induced pluripotent stem cell (iPSC)-derived clinical-grade corneal endothelial cells (CECs) generation and cryopreservation through the neural crest cell (NCC) lineage using peripheral blood as a donor source and hESCs maximizes the availability of these vital cells for treating the corneal endothelial disease as an alternative to donor corneas for corneal endothelium (CE) transplantations and other applications.

Provided are antigen-specific T cell compositions of making the same. In some embodiments, the present technology comprises T cell compositions that are expresses to one or more of CD2, CD3, or CD28. In some embodiments, the T cell compositions of the present technology are donor derived. In some embodiments, the T cell compositions are generated by the steps of (a) isolating a T cell population from a donor; (b) culturing the T cell population with one or more cytokines; (c) culturing the T cell population with one or more antibodies selected from the group consisting of an anti-CD3 antibody, an anti-CD28 antibody, and an anti-CD2 antibody; and (d) expanding the T cell population for a period of time sufficient to generate the T cell composition.

Described herein are kits, compositions, and methods for detecting porcine antigens in a biological sample. The kit comprises a support, an anti-porcine antibody coupled to the support, and instructions for preparing a lysate from a porcine donor source and contacting the lysate with the anti-porcine antibody. The kit can be used to determine the risk of graft rejection in a human subject accepting or considering graft from a porcine donor.

In alternative embodiments, provided are products of manufacture and methods for treating, ameliorating and preventing diseases and conditions related to infected or dysfunctional mucosal surfaces, including mucosal surfaces in the gastrointestinal (GI) tract, respiratory tract, and other mucosal surfaces, for example, mucosal surfaces in the stomach, nasal sinuses, nasopharyngeal area, lungs, bladder or the vagina. Provided are methods and products of manufacture for preparing the GI tract for a microbiota engraftment, then infusing a colonic microbiota engraftment, for example, a fecal microbiota transplant (FMT). In alternative embodiments, provided are methods and products of manufacture for mechanical disruption of a biofilm followed by the chemical and / or biologic dissolution of a mucus layer or a biofilm, and subsequent implantation of FMT material into or onto a mucosal surface such as a GI tract. In alternative embodiments, provided are delivery devices which permit the FMT material to reach the various mucosal surfaces, for example, mucosal surfaces in the GI tract. In alternative embodiments, provided are methods and products of manufacture for replacing an individual's microbiome, where the individual's microbiome may be infected, including replacing the individual's microbiome in colonic, intestinal, gastric, respiratory or vaginal spaces or environments, with that of a healthy or not infected microbiome, where the healthy or not infected microbiome can be donor-derived or cultured. Provided herein are methods for the treatment, amelioration and / or prevention of numerous conditions characterized by an in situ microbiome super-infection, including microbiome super-infections, for example, conditions characterized as gastrointestinal (GI) disease.

The invention discloses application of mitochondrial transplantation based on skeletal muscle migrators in repairing damaged neurons in cerebral apoplexy. Researches prove that drug stimulation, electrical stimulation and movement can induce skeletal muscle to generate the migrators, and the migrators are identified to not only contain mitochondria with a complete structure, but also contain a plurality of mitochondria function supporting substances. Therefore, an important basis is provided for applying the skeletal muscle transporter to mitochondrial transplantation treatment. It is further found that the curative effect of repairing the cerebral apoplexy damaged neurons through mitochondrial transplantation based on the skeletal muscle transporter is remarkably superior to that of pure mitochondrial transplantation treatment. Besides, the skeletal muscle transporter can be administered through intravenous infusion and has the targeting property to neurons on the stroke focus side, so that the clinical transformation possibility and transplantation efficiency of mitochondrial transplantation treatment are greatly improved. Therefore, the key bottlenecks of lack of donor sources, insufficient targeting, low transplantation efficiency and the like in the current mitochondrial therapy are successfully overcome, and a technical foundation is laid for clinical transformation of the mitochondrial therapy.

The invention provides a method for reconstructing functional gametes of fish cryopreserved germline stem cells based on zebra fish nanos2- / -mutant receptors, which specifically comprises the following steps: S1, collecting embryos of selfing progenies of zebra fish nanos2- / -and nanos + / -mutants, culturing and screening out nanos2- / -mutants to obtain receptor fish; s2, after gonads of the cryopreserved fishes are recovered, donor fish germline stem cells are obtained; s3, transplanting the germline stem cells of the body fish in the step S2 into the receptor fish in the step S1, culturing to obtain positive individuals, and continuously culturing to obtain the functional gametes of the zebra fish. Based on a selection strategy taking a nanos2 <- / -> mutant receptor as an excellent receptor, verification is carried out in experimental animal zebra fish cryopreserved germline stem cells: colonization and differentiation of germline stem cells from a donor source can be effectively supported, so that functional ova and sperms are generated, and the limitation that donor ova are difficult to obtain in an existing belly borrowing reproduction technology is broken through; and a new way is provided for long-term preservation and recovery of fish germplasm resources.

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

The present invention relates to a method for selecting a donor source for NK cells with improved proliferation capacity, which is characterized by identifying a specific single nucleotide polymorphism in the CISH gene. The present invention solves the problem of NK cell efficacy varying depending on the donor source in cell therapy agents containing NK cells, and enables the production of consistent NK cells with excellent proliferation capacity.

The invention belongs to the technical field of experimental animal model construction, and particularly relates to a method for constructing an arteriosclerosis mouse model by using humanized flora. The technical problem to be solved by the invention is to establish an arteriosclerosis phenotype humanized mouse model taking intestinal flora of a patient with coronary artery disease as a donor source. According to the technical scheme, the method for constructing the arteriosclerosis mouse model by using the humanized flora comprises the following steps: collecting an excrement sample of a patient diagnosed as arteriosclerosis, and preparing a flora suspension; the sterile mouse is subjected to gavage, gavage is conducted once every other day, and gavage is conducted five times; lavage is carried out once a week; and the whole process lasts for 10-13 weeks from the beginning of gavage. The mouse model constructed by the method can systematically evaluate key pathological phenotypes of hypercholesteremia, vascular dysfunction, immune activation and the like of the mouse.

The invention provides a method for constructing a hepatic progenitor cell-like cell bank, including successively performing following processes to human primary hepatocyte cultures from different donor sources: transformation-culture, cryopreservation treatment, proliferation-culture, a first subculture treatment, virus infection, a second subculture treatment, continuous selection-culture and continuous subculture. In the method for constructing a heterogenous immortal hepatic progenitor cell-like cell bank of the present invention, the human primary hepatocyte culture of each of the donor sources is transformation-cultured before the proliferation-culture, which is beneficial in endowing the human primary hepatocyte cultures with good proliferation performance. Once combined with subsequent controlling of culture parameter, the immortal hepatic progenitor cell-like cell lines obtained from different donor sources may have good in vitro proliferation ability. The invention also provides an application of the hepatic progenitor cell-like cell bank and cell lines obtained by the construction method.

The invention belongs to the technical field of genetic breeding of aquatic animals, and particularly relates to a method for producing male gametes of finless eels based on a germline stem cell transplantation technology. The method comprises the following steps: firstly, obtaining a cell suspension from gonads of one-year-old female ricefield eel, centrifuging to obtain germline stem cells, adding a fluorescent label, injecting the germline stem cells into bodies of receptor fish two-year-old male mastacembelus armatus, checking testis of the mastacembelus armatus by using a fluorescence microscope, selecting the receptor mastacembelus armatus subjected to colonization differentiation of the germline stem cells of the ricefield eel, breeding to a breeding season the male gametes for artificial insemination of the ricefield eels are obtained. According to the method for special germ cell allograft and functional gamete generation of ricefield eel, donor-sourced gamete can be generated in a short time, the problems of long ricefield eel breeding period, breeding difficulty and the like are solved, and the method has important significance on ricefield eel research and large-scale breeding.

The invention belongs to the technical field of biological medicine, and discloses a xenogenic heart transplantation donor source cfDNA quantitative detection kit based on SNP typing. The kit is characterized in that donor-specific SNP sites and myocardial / endothelial cell differential methylation CpG sites are integrated, an SNP anchoring and methylation analysis two-dimensional molecular traceability system is constructed, cfDNA fragments containing SNP-CpG units are amplified or captured in a targeted mode, bioinformatics analysis is combined, circulating free DNA of a myocardial source and circulating free DNA of an endothelial source are quantified respectively, and the molecular traceability of the myocardial / endothelial cell is improved. And judging cellular rejection or antibody-mediated rejection according to the ratio and a threshold value. The kit disclosed by the invention not only has high engineering feasibility and clinical applicability, but also realizes cognitive transition from whether the cells are damaged to what kind of cells are damaged by what mechanism on the molecular diagnosis level, and provides a key tool for precise immune management of xenotransplantation.

Disclosed herein includes a method for assessing an organ transplant by longitudinal monitoring of donor-derived cfDNA (dd-cfDNA) using a machine learning approach. Defining longitudinal dd-cfDNA trends is challenging due to differences in individual baselines and sampling frequency as well as disease-related fluctuations. Here we show that an unsupervised machine learning approach, based on dynamic time warping distances, enables differentiation of dd-cfDNA trajectories after rejection diagnosis into groups that correlate with outcomes, and provides an improved computerized systems for predicting an outcome of an organ transplant or treatment of organ transplant rejections. In addition, this disclosure provide approaches for combining dd-cfDNA measurements with clinical data to further assess organ transplant rejection and discriminate between rejection subtypes.

This invention relates to γδT cell culture technology, specifically a method and application for activating γδT cells using circulating tumor cells (CTCs) or their derivatives. The method includes obtaining donor-derived γδT cells; obtaining CTCs or their derivatives from cancer patients; and co-culturing the γδT cells with the CTCs or their derivatives in an in vitro co-culture system, thereby activating the γδT cells under the stimulation of the CTCs or their derivatives to obtain CTC-γδT cells. This invention utilizes patient-derived circulating tumor cells as the activation stimulus for γδT cells, enabling the resulting γδT cells to recognize tumor-associated antigens and personalized neoantigens, overcoming tumor heterogeneity and antigen escape problems.

The application discloses a research method for tumor cell influence mechanism of monocyte remodeling based on bone marrow inflammatory microenvironment, and relates to the technical field of tumor treatment; and comprises the following steps: S1, providing bone marrow plasma from a classic myeloproliferative neoplasm patient; S2, placing primary CD14+ monocytes from a healthy donor in an in-vitro culture system containing the bone marrow plasma, inducing phenotype remodeling of the monocytes, and obtaining the remodeling monocytes. The application establishes CD163+CD206+ double-positive remodeling monocytes as a new target for MPN treatment; through comparison experiments of direct co-culture and indirect co-culture by Transwell, it is confirmed that the promotion effect of the remodeling monocytes on HEL cell proliferation strictly depends on physical contact between cells, rather than soluble secreted factors; and the application provides a theoretical basis for developing new antibody drugs or small molecule inhibitors for blocking cell-cell interaction.

The invention belongs to the technical field of cell biology, and provides a method for reprogramming autologous urogenic stem cell pedigree of a hepatic failure patient into hepatocyte-like cells by in-vitro chemical induction, which comprises the following steps: separating and culturing from sterile urine of the hepatic failure patient to obtain urogenic stem cells of the hepatic failure patient; the urine-derived stem cell lineage of a hepatic failure patient is chemically induced in vitro to be reprogrammed into hepatocyte-like cells. By combining the autologous USCs of the patient with the chronic and acute hepatic failure with a pure chemical lineage reprogramming technology, the limitation of the traditional HLCs preparation method in the aspects of donor source, safety, induction efficiency and standardization is overcome, and safe and standardized preparation of the hepatocyte-like cells is also realized. A novel technical approach and a novel cell source are provided for clinical application such as bioartificial liver and hepatocyte transplantation treatment, and outstanding technical progress and application prospects are achieved.

A method for preparing enriched cells is provided. The cells may be from a single donor or from two or more donors. The method includes removing dying or dead cells from primary cells from the donor(s) by a density gradient separation to generate separated cells; cryopreserving the separated cells to generate cryopreserved separated cells; thawing the cryopreserved separated cells to generate thawed separated cells; and removing dying or dead cells from the thawed separated cells by subsequent density gradient separation(s). The primary cells from two or more donors may be combined before or after the first density gradient separation to provide pooled enriched cells. The enriched cells may have a viability rate greater than the primary cells from the donor(s). Also provided is a product including the enriched cells (which may be pooled enriched cells) and methods for using the enriched cells or the product including the enriched cells.

Disclosed herein includes a method for assessing a lung transplant, comprising extracting cfDNA from a blood sample of a lung transplant recipient; preparing a sequencing library from the extracted cell-free DNA and performing high-throughput sequencing on the sequencing library; quantifying an amount of donor-derived cell-free DNA and / or a percentage of donor-derived cell-free DNA; quantifying an amount of one or more inflammatory mediators in a blood sample or a bronchoalveolar lavage sample of the lung transplant recipient and / or a performance of the lung transplant recipient in one or more physiological tests; and performing a multi-modal assessment to determine the presence or absence of chronic lung allograft dysfunction (CLAD) in the lung transplant recipient.

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and / or senescent cells. The donor quiescent and / or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and / or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ϵ-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.